These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 8619596)
1. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Yuen GJ; Drusano GL; Fletcher C; Capparelli E; Connor JD; Lalezari JP; Drew L; Follansbee S; Busch D; Jacobson M Antimicrob Agents Chemother; 1995 Oct; 39(10):2350-2. PubMed ID: 8619596 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361 [TBL] [Abstract][Full Text] [Related]
3. Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. Piketty C; Bardin C; Gilquin J; Mahe V; Kazatchkine MD; Chast F J Infect Dis; 1996 Jul; 174(1):188-90. PubMed ID: 8655992 [TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis; 1997 Jul; 176(1):50-8. PubMed ID: 9207349 [TBL] [Abstract][Full Text] [Related]
5. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. Freeman RB Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014 [TBL] [Abstract][Full Text] [Related]
7. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Flores-Aguilar M; Kuppermann BD; Quiceno JI; Dankner WM; Wolf DG; Capparelli EV; Connor JD; Sherwood CH; Fullerton S; Gambertoglio JG Ophthalmology; 1993 Jul; 100(7):1022-31. PubMed ID: 8391674 [TBL] [Abstract][Full Text] [Related]
8. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. Jacobson MA; O'Donnell JJ J Acquir Immune Defic Syndr (1988); 1991; 4 Suppl 1():S11-5. PubMed ID: 1848616 [TBL] [Abstract][Full Text] [Related]
9. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Razonable RR; Paya CV Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169 [TBL] [Abstract][Full Text] [Related]
10. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Arevalo JF; Garcia RA; Mendoza AJ Eur J Ophthalmol; 2005; 15(5):610-8. PubMed ID: 16167292 [TBL] [Abstract][Full Text] [Related]
11. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. Jacobson MA; Drew WL; Feinberg J; O'Donnell JJ; Whitmore PV; Miner RD; Parenti D J Infect Dis; 1991 Jun; 163(6):1348-51. PubMed ID: 1645385 [TBL] [Abstract][Full Text] [Related]
12. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial. Díaz-Llopis M; Martos MJ; España E; Cervera M; Vila AO; Navea A; Molina FJ; Romero FJ Doc Ophthalmol; 1992; 82(4):297-305. PubMed ID: 1339115 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. Spector SA; Busch DF; Follansbee S; Squires K; Lalezari JP; Jacobson MA; Connor JD; Jung D; Shadman A; Mastre B J Infect Dis; 1995 Jun; 171(6):1431-7. PubMed ID: 7769276 [TBL] [Abstract][Full Text] [Related]
18. Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Zaknun D; Zangerle R; Kapelari K; Fischer H; Sailer M; McIntosh K Pediatr Infect Dis J; 1997 Aug; 16(8):807-11. PubMed ID: 9271045 [No Abstract] [Full Text] [Related]
19. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Piketty C; Bardin C; Gilquin J; Gairard A; Kazatchkine MD; Chast F Clin Microbiol Infect; 2000 Mar; 6(3):117-20. PubMed ID: 11168085 [TBL] [Abstract][Full Text] [Related]
20. [Ganciclovir-resistant cytomegalovirus infection: 2 cases with different clinical impact]. Reusser P; Hostettler B; Attehbofer R Schweiz Med Wochenschr; 1996 Oct; 126(42):1779-84. PubMed ID: 8966510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]